SamanTree Medical Achieves FDA Clearance for Histolog® Scanner, Ushering in a New Era of Tissue Imaging in the U.S.
September 13 2024 - 2:00AM
Business Wire
SamanTree Medical, a leader in innovative surgical imaging
solutions, today announced that it has received FDA 510(k)
clearance of its Histolog® Scanner for imaging of the internal
microstructure of tissues including, but not limited to, the
identification of cells, vessels and their organization or
architecture. This groundbreaking Swiss made device is designed to
provide real-time, highresolution imaging of fresh tissue surfaces,
offering surgeons and pathologists this information for excised
tissue.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240912995435/en/
The Histolog Scanner in use for rapid
visualization of fresh tissue microstructures. (Photo: SamanTree
Medical)
The Histolog® Scanner enables real-time, ultra-fast confocal
microscopy, allowing for the immediate imaging of resected tissues.
This advancement aims to enable physicians to improve their
efficiency.
“We are thrilled to introduce the Histolog® Scanner to the U.S.
market,” said Dr. Charles Carignan, Executive Chairman of SamanTree
Medical. “This FDA clearance is a significant milestone for the
company. The ability of the Histolog® Scanner to produce real-time
imaging of the internal microstructure of tissues provides surgeons
and pathologists with immediate, actionable information.”
Prof. Dr. Alex Mottrie, Head of the Urological Department OLV
Hospital, Aalst, Belgium and CEO of ORSI Academy, Ghent, Belgium,
commented on the impact of this new technology: “The Histolog®
Scanner represents cutting-edge technology in imaging of freshly
excised tissue. Its ability to provide high-resolution, real-time
images allows us to make more informed decisions.”
Prof. Dr. Ari D. Brooks, Director of Endocrine and Oncologic
Surgery, Pennsylvania Hospital, Philadelphia, PA said “The Histolog
technology has the potential to significantly reduce the cost,
resources and delays associated with the current lack of real-time
high-resolution imaging”. Prof Dr. Douglas Scherr, Clinical
Director of Urologic Oncology at the Weill Medical College of
Cornell University said “Providing imaging data at this resolution
has the potential to aid in patient care. In our practice and
across Urology, as a field, we are facing limitations in the
ability to provide timely decisions to our patients. We will count
on the Histolog Scanner to provide us with the ability to image the
tissues’ microstructures in real-time and to enable us to make
immediate decisions.”
The FDA clearance of the Histolog® Scanner marks a crucial
moment in SamanTree Medical’s mission to expand its innovative
imaging solutions globally. With this clearance, SamanTree is set
to accelerate its U.S. market entry, ensuring that more healthcare
providers can leverage the benefits of this cutting-edge
technology.
About SamanTree Medical
SamanTree Medical is committed to enhancing clinical outcomes
through the development of advanced imaging technologies. The
Histolog® Scanner, now FDA-cleared, offers realtime,
high-resolution imaging of excised tissue surfaces, providing
physicians with this information for immediate assessments.
Following the initial commercialization in Europe, the Histolog®
Scanner is poised to make a significant impact in the U.S.
healthcare market.
For more information, visit www.samantree.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240912995435/en/
Contact Information Olivier Delporte CEO, SamanTree
Medical info@samantree.com